Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer

PURPOSE: No effective systemic therapy exists for patients with metastatic low-grade serous (LGS) ovarian cancers. BRAF and KRAS mutations are common in serous borderline (SB) and LGS ovarian cancers, and MEK inhibition has been shown to induce tumor regression in a minority of patients; however, no...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Oncol
Hlavní autoři: Grisham, Rachel N., Sylvester, Brooke E., Won, Helen, McDermott, Gregory, DeLair, Deborah, Ramirez, Ricardo, Yao, Zhan, Shen, Ronglai, Dao, Fanny, Bogomolniy, Faina, Makker, Vicky, Sala, Evis, Soumerai, Tara E., Hyman, David M., Socci, Nicholas D., Viale, Agnes, Gershenson, David M., Farley, John, Levine, Douglas A., Rosen, Neal, Berger, Michael F., Spriggs, David R., Aghajanian, Carol A., Solit, David B., Iyer, Gopa
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2015
Témata:
Biology of Neoplasia
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4669594/
https://ncbi.nlm.nih.gov/pubmed/26324360
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.62.4726
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky